|
|
|
| Clinical efficacy of Cabergoline in the treatment of female hyperprolactinemia |
| SU Yaqin ZHANG Ningning LIANG Xiaoqing ZHANG Shaojing WEI Yongzhi |
| Department of Gynaecology, the First Hospital of Shijiazhuang City, Hebei Province, Shijiazhuang 050011, China |
|
|
|
Abstract Objective To explore the application value of Cabergoline in the treatment of abnormal menstruation and galactorrhea in women with hyperprolactinemia. Methods Patients with hyperprolactinemia treated from June 2014 to June 2017 in the First Hospital of Shijiazhuang City were selected. They were divided into two groups according to the random number table. The observation group (n = 45) was treated with Cabergoline, while the control group (n = 45) was treated with Bromocriptine. Before and after treatment, the changes of the serum prolactin value, the clinical symptom effect, the incidence of drug adverse reaction and the drug resistance of the two groups were recorded. Results The serum prolactin values of observation group at 2 and 3 months after treatment were lower than those of control group (P < 0.05). The effective rate of abnormal menstruation in observation group was higher than that of control group (P < 0.05). There was no statistically significant difference in treatment efficiency between the two groups for galactorrhea, visual impairment, headache and other symptoms (P > 0.05). The incidence of adverse reaction such as nausea, vomiting, hypotension, and mental symptoms in observation group were lower than those in control group (P < 0.05). There was no statistically significant difference in drug resistance rate between two groups (P > 0.05). Conclusion Compared with the Bromocriptine, Cabergoline has better effect on reducing prolactin value, improvement of abnormal menstruation and lower incidence of drug adverse reactions in women with hyperprolactinemia.
|
|
|
|
|
|
[1] Abdel HAM，Borg TF，Madkour WA. Prevalence of hyperprolactinemia and thyroid disorders among patients with abnormal uterine bleeding [J]. Int J Gynecol Obstet，2015， 131（3）：273-276.
[2] Gordon CM，Ackerman KE，Berga SL，et al. Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline [J]. J Clin Endocrinol Metab，2017，102（5）：1413-1439.
[3] 贺晶.卡麦角林与溴隐亭治疗高泌乳素血症对比研究[J].现代仪器与医疗，2015，21（4）：25-26，43.
[4] 杨强，陈晋，刘军.卡麦角林治疗泌乳素型垂体瘤的研究进展[J].中国神经精神疾病杂志，2016，42（5）：311-314.
[5] 中国垂体腺瘤协作组.中国垂体催乳素腺瘤诊治共识[J].中华医学杂志，2014，94（31）：2406-2411.
[6] 田倩玉，杨欣.无妊娠要求的高泌乳素血症治疗策略及监测[J].实用妇产科杂志，2016，32（7）：487-489.
[7] 刘玉彩，魏兰英.口服溴隐亭治疗垂体泌乳素腺瘤的不良反应及早期护理干预[J].中国医药导报，2016，13（11）：142-145.
[8] 张湘衡，牟永告，赛克，等.垂体泌乳素腺瘤患者溴隐亭耐药与血清PRL水平的关系[J].广东医学，2011，32（3）：306-308.
[9] 莫琳玲，王艳姣.溴隐亭治疗高泌乳素血症并合不孕的临床分析[J].实用妇科内分泌电子杂志，2015，2（12）：85-86.
[10] 徐秀玲.育龄期妇女高泌乳素血症的病因与治疗[J].浙江创伤外科，2014，19（2）：298-299.
[11] Wang AT，Mullan RJ，Lane MA，et al. Treatment of hyperprolactinemia：a systematic review and meta-analysis [J]. Syst Rev，2012，24（1）：33.
[12] Webster J，Piscitelli G，Polli A，et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea [J]. N Engl J Med，1994，331（14）：904-9.
[13] Xia MY，Lou XH，Lin SJ，et al. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia：a systematic review and meta-analysis [J]. Endocrine，2018， 59（1）：50-61.
[14] Glezer A，Jallad RS，Machado MC，et al. Pregnancy and pituitary adenomas [J]. Minerva Endocrinol，2016，41（3）：341-350.
[15] 邓洁，罗剑波，彭聪，等.溴隐亭对高泌乳素血症所致不孕不育女性患者性激素水平及妊娠率的影响[J].中国妇幼保健，2017，32（14）：3260-3262.
[16] An FR，Yang R，Wang ZM，et al. Hyperprolactinemia，prolactin-related side effects and quality of life in Chinese psychiatric patients [J]. Compr Psychiatry，2016，（71）：71-76.
[17] 王佳宁，阮祥燕.高泌乳素血症的病因及诊疗进展[J].医学综述，2012，18（21）：3629-3632.
[18] Halperin RI，Cámara GR，García MM，et al. Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia [J]. Endocrinol Nutr，2013，60（6）：308-19.
[19] 石苗.溴隐亭对高泌乳素血症女性促性腺激素诱导排卵的影响[J].中国妇幼保健，2015，30（30）：5157-5159.
[20] 母义明.垂体瘤诊治进展[J].解放军医学杂志，2017，42（7）：576-582. |
|
|
|
